Lavie bio successfully secures second half advance payment of $2.5m after meeting corteva's licensing agreement requirements

The payment completes the $5m advance payment received under the licensing agreement for bio-fungicide product candidates rehovot, israel , feb. 28, 2024 /prnewswire/ -- lavie bio ltd., a leading ag-biologicals company that develops microbiome-based, computational-driven bio-stimulant and bio-pesticide novel products, and a subsidiary of evogene ltd.
CTVA Ratings Summary
CTVA Quant Ranking